The Biotechnology Department is equipped to develop and produce monoclonal antibodies (mAbs), biosimilars, recombinant proteins and other NBEs (New Biological Entities).


Thanks to the technical skills of the specialized staff, the whole production process is followed: from the preliminary development phase (lab scale) and analytical characterization to cGMP manufacturing (authorized cGMP department for investigational active substances).


Right from the very first phases of product development, experiments are planned and organized by applying the DoE (Design of Experiment) method according to QbD (Quality by Design) principles. Reliable and scalable process are setted in order to cut down times/costs and having a high quality standard.


For each manufacturing phase, the department is equipped with state-of-the-art technologies,  prefering single-use solutions to guarantee the maximum process flexibility and product quality.

scala pilota
scala pilota



  • Expression platform based on a mammalian cell line (CHO) validated and compliant with GMPs
  • Expression in E.coli (not GMP)


  • single-use Wave bioreactors (2x25L)
  • single-use stirred-tank bioreactor (200L)
  • CO2 incubators


  • single-use stirred-tank bioreactor (10L)
  • single-use Wave bioreactor (25L)
  • CO2 incubator
  • bacterial cultures incubator (6L)


  • pilot scale chromatography system
  • single-use chromatography system
  • single-use tangential filtration system


  • chromatography systems (FPLC)
  • tangential filtration system


  • Single-use mixer (10-50L)
  • Single-use mixer (200L)


  • HPLC
  • UV-Vis spectrophotometer
  • Capillary electrophoresis
  • imaging systems
  • ELISA reader
  • ELISA plate washer
  • BioLayerInterferometry
  • Cell-based potency assays
  • Real-Time PCR
  • Flow cytometer

Thank you

We sent you an email. To activate the newsletter click on the link you will find in the message, thank you!


Private area

Log in to restricted area


Notice on the treatment of personal data

Dear visitor, in the following sections we will describe how the reserved area of the website is managed as far as processing personal data of users. The notice is issued pursuant to art. 13 of EU Regulation 679/2016 (hereinafter also the Regulation) on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and applies to those who interact with the website of Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (hereinafter I.B.I.), which can be accessed at the following address:, the opening page of the official I.B.I. website. The notice only applies to the I.B.I. website. It does not apply to any other websites that the user may access through links.

  1. The processing of the personal data that you supply, which are also used for the creation of your user profile, and which will be included in the “Doctors’ Details” database, has the following purposes:
  • carry out medical sales related activities for drugs for human consumption. Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. and Ibigen S.r.l., part of the same company group (hereinafter also Ibigen Group), carry out such activities in compliance with the provisions of the current regulations, with particular, but not exclusive, attention to Italian Legislative Decree no. 219 of 24.04.2006 and subsequent modifications. In view of the objectives of the Ibigen Group, it is important to point out that the processing activities do not deal with any special data. The supply of the data for the medical sales activities is necessary, and failure to provide consent will make it impossible for us to fulfil the above objectives;

  • forwarding of invitations or information on congresses, conferences, seminars, communications on initiatives promoted or sponsored by the Ibigen group, regular or occasional publications, information on new products, methods and services. Such activities are carried out by e-mail, fax, SMS, normal post or telephone. The supply of the data for such purposes is optional, and failure to supply them will result in the information not being forwarded.

  1. As far as the creation of your profile on our website, we remind you that your password is strictly confidential and should not be disclosed.
  2. Your data will not be disclosed, but may be shared with individuals, companies, associations or professional studios providing support or consultancy services to the Ibigen Group, the medical sales representative network, our suppliers and any sub-suppliers - from time to time entrusted with activities connected with the above objectives -, mailing or statistical survey companies, or companies for the forwarding of scientific documentation, and individuals authorised to access the data by law and/or pursuant to secondary regulations.
  3. Such people may only acquire knowledge of your personal data for the above mentioned purposes.
  4. The Owners of the Treatment (Data Controllers) are the two companies of the Ibigen Group with legal headquarters at Via Fossignano no. 2, Aprilia (LT), Italy.
  5. Personal data are processed using manual and automated means, for the time necessary for reaching the objectives for which they were collected. Special safety measures are in place to avoid data loss, unlawful or incorrect use and unauthorised access.
  6. Lastly, we also inform you that you can at any time exercise the rights contemplated by the Regulation, and in particular request access to the data, their correction, update and block, or you can withdraw your consent, or request the limitation of the processing or the cancellation of the data. As data subject, you also have the right to issue a complaint with the relevant control Authority. Such rights may be exercised in writing to the following e-mail address:
  7. The Data Protection Officer may be contacted at the following e-mail address:

* Required fields